Polyethylene glycol based prodrug of adrenomedullin and use thereof

US10035818B2 · kind B2 · utility

Assignees

• Bayer Pharma Aktiengesellschaft · DE
• Bayer Intellectual Property GmbH · DE

Inventors

• Ingo Flamme · Bergneustadt, DE
• Johannes Köbberling · Neuss, DE
• Hans-Georg Lerchen · Leverkusen, DE
• Nils Griebenow · Milford, US
• Rudolf Schohe-Loop · Wuppertal, DE
• Sven Wittrock · Berlin, DE
• Maria Köllnberger · Velbert, DE
• Frank Wunder · Wuppertal, DE
• Gorden Redlich · Bochum, DE
• Andreas Knorr · Erkrath, DE
• Julie Marley · Stockton, GB
• Iain Pritchard · Stockton, GB

Key dates

• Filing date: Mar 29, 2017
• Grant date: Jul 31, 2018
• Expiry date: Mar 29, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/575
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.